SCHEMBL40513

SCHEMBL40513

[CH2]C(C)C12CC3CC(CC(C3)C1)C2

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A2 O15244 2/20 0.56
SLC47A1 Q96FL8 2/20 0.56
MAPT P10636 1/20 0.54
NPC1 O15118 1/20 0.42
ALDH1A1 P00352 1/20 0.42
GRIN2D O15399 4/20 0.41
GRIN3B O60391 4/20 0.41
GRIN1 Q05586 4/20 0.41
GRIN2A Q12879 4/20 0.41
GRIN2B Q13224 4/20 0.41
GRIN2C Q14957 4/20 0.41
GRIN3A Q8TCU5 4/20 0.41
EPHX2 P34913 5/20 0.38
GAA P10253 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
SLC22A1 O15245 1/20 0.35
LMNA P02545 1/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23111396 0.79 SLC22A2 (0.50) SLC22A2SLC47A1MAPTNPC1ALDH1A1
SCHEMBL677940 0.77 SLC22A2 (0.62) SLC22A2SLC47A1MAPTNPC1ALDH1A1
SCHEMBL455611 0.77 SLC22A2 (0.62) SLC22A2SLC47A1MAPTNPC1ALDH1A1
SCHEMBL138375 0.77 SLC22A2 (0.62) SLC22A2SLC47A1MAPTNPC1ALDH1A1
SCHEMBL27740239 0.75 SLC22A2 (0.48) SLC22A2SLC47A1MAPTNPC1ALDH1A1
SCHEMBL10791429 0.74 SLC22A2 (0.36) SLC22A2SLC47A1MAPTGRIN2DGRIN3B
SCHEMBL182779 0.72 SLC22A2 (0.56) SLC22A2SLC47A1MAPTNPC1ALDH1A1
SCHEMBL7467574 0.72 SLC22A2 (0.56) SLC22A2SLC47A1MAPTNPC1ALDH1A1
SCHEMBL7739624 0.72 SLC22A2 (0.56) SLC22A2SLC47A1MAPTNPC1ALDH1A1
Rimantadine SCHEMBL2981 0.72 SLC22A2 (1.00) SLC22A2SLC47A1MAPTNPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210166935-A1 METHOD AND COMPOSITION FOR SELECTIVELY MODIFYING BASE MATERIAL SURFACE JSR CORPORATION (JP) 2021-06-03 US claimed
US-10950438-B2 Method and composition for selectively modifying base material surface JSR CORPORATION (JP) 2021-03-16 US claimed
US-12030970-B2 Curable composition and stereolithographic resin composition comprising same KURARAY CO., LTD. (JP) 2024-07-09 US disclosed
US-20240158547-A1 COMPOSITION AND POLYMER TOKYO OHKA KOGYO CO., LTD. (JP) 2024-05-16 US disclosed
EP-3900693-B1 USE OF A RESIN COMPOSITION KURARAY NORITAKE DENTAL INC (JP) 2024-03-20 EP disclosed
US-11814454-B2 Curable composition, and resin composition for stereolithography prepared therefrom KURARAY CO., LTD. (JP) 2023-11-14 US disclosed
EP-4268792-A1 ADHESIVE COMPOSITION FOR PHOTOFABRICATION ARTICLES Kuraray Noritake Dental Inc. (JP) 2023-11-01 EP disclosed
WO-2023190931-A1 RESIN COMPOSITION FOR STEREOLITHOGRAPHY クラレノリタケデンタル株式会社 2023-10-05 WO disclosed
WO-2023182514-A1 ADHESIVE COMPOSITION FOR STEREOLITHOGRAPHIC ARTICLE AND NON-STEREOLITHOGRAPHIC ARTICLE クラレノリタケデンタル株式会社 2023-09-28 WO disclosed
US-11705331-B2 Method and composition for selectively modifying base material surface JSR CORPORATION (JP) 2023-07-18 US disclosed
US-11603480-B2 Composition for underlayer film formation, underlayer film for directed self-assembled film and forming method thereof, and directed self-assembly lithography process JSR CORPORATION (JP) 2023-03-14 US disclosed
EP-1000924-A1 ACID-SENSITIVE COMPOUND AND RESIN COMPOSITION FOR PHOTORESIST Daichel Chemical Industries Ltd (JP) 2000-05-17 EP disclosed
WO-1999055664-A1 PREPARATION OF CARBOCYCLIC COMPOUNDS GILEAD SCIENCES, INC. (US) 1999-11-04 WO disclosed
EP-0938475-A1 PIPERIDINE COMPOUNDS GILEAD SCIENCES, INC. (US) 1999-09-01 EP disclosed
EP-0920410-A1 PREPARATION OF CYCLOHEXENE CARBOXYLATE DERIVATIVES GILEAD SCIENCES, INC. (US) 1999-06-09 EP disclosed
WO-1999014185-A1 COMPOUNDS CONTAINING SIX-MEMBERED RINGS, PROCESSES FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS GILEAD SCIENCES, INC. (US) 1999-03-25 WO disclosed
WO-1999010365-A2 5',5'-LINKED OLIGOMERS HAVING ANTI-THROMBIN ACTIVITY GILEAD SCIENCES, INC. (US) 1999-03-04 WO disclosed
WO-1998034603-A1 USE OF BETULIN AND ANALOGS THEREOF TO TREAT HERPESVIRUS INFECTION REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 1998-08-13 WO disclosed
WO-1998017647-A1 PIPERIDINE COMPOUNDS GILEAD SCIENCES, INC. (US) 1998-04-30 WO disclosed
WO-1998007685-A1 PREPARATION OF CYCLOHEXENE CARBOXYLATE DERIVATIVES GILEAD SCIENCES, INC. (US) 1998-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11814454-B2 Curable composition, and resin composition for stereolithography prepared therefrom WASF2, COPE, ARCN1 SLC22A2 2509/4885SLC47A1 4388/4885MAPT 1556/4885
US-12030970-B2 Curable composition and stereolithographic resin composition comprising same ARL1, ASH2L, VCL SLC22A2 4391/4885SLC47A1 4655/4885MAPT 2133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.